Department of Pediatric Cardiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Cardiol Young. 2023 Sep;33(9):1741-1742. doi: 10.1017/S1047951123000483. Epub 2023 Mar 20.
Colchicine is an FDA-approved medicine that has been used for many years to prevent and treat gout flares as well as familial mediterranean fever. It is also used off-label to treat pericarditis, calcium pyrophosphate illness, and Behçet's syndrome. There are additional studies on the use of colchicine, which is accepted as the standard treatment for pericarditis in adults, post-pericardiotomy syndrome, post-operative and post-ablation atrial fibrillation, coronary artery disorders, prior to percutaneous coronary procedures, and myocarditis. Colchicine appears to be a promising oral cardiovascular treatment targeting the inflammatory axis, owing to its low cost and moderate side-effect profile. Our aim is to emphasise that colchicine treatment, which has a strong and effective anti-inflammatory effect profile, should be kept in mind in addition to conventional treatment in childhood myocarditis.
秋水仙碱是一种经美国食品药品监督管理局批准的药物,已使用多年,用于预防和治疗痛风发作以及家族性地中海热。它也被超适应证用于治疗心包炎、焦磷酸钙沉积病和贝切特综合征。还有一些关于秋水仙碱的使用研究,该药被认为是成人心包炎的标准治疗方法,还用于心包切开术后综合征、术后和消融后心房颤动、冠状动脉疾病、经皮冠状动脉介入前和心肌炎。由于成本低且副作用适中,秋水仙碱作为一种针对炎症轴的有前途的口服心血管治疗药物。我们的目的是强调,在儿童心肌炎的常规治疗之外,还应考虑具有强大和有效抗炎作用的秋水仙碱治疗。